Impact of coaching patients on coronary risk factors: Lessons from The COACH Program

Disease Management and Health Outcomes

Volumn 13, Issue 4, 2005, Pages 225-244

  Vale, Margarite J ^a,b   Jelinek, Michael V ^c   Best, James D ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c St Vincent's Hospital Melbourne ^*

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER PROGRAM; CORONARY RISK; COUNSELING; HEALTH EDUCATION; HEART REHABILITATION; HUMAN; ISCHEMIC HEART DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; REVIEW; RISK FACTOR; RISK MANAGEMENT;

EID: 23744506391     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200513040-00002     Document Type: Review

References (128)

1. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-7
2. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 1577-9
3. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-33
4. Tuomilehto JT, Lindström J, Eriksson JG, et al. , for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
5. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: CARE (Cholesterol and Recurrent Events Trial). N Engl J Med 1996; 355: 1001-9
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339: 1349-57
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,546 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
11. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major adverse cardiovascular events: results of prospectively-designed overview of randomised trials. Lancet 2003; 362: 1527-35
12. Jollife JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
14. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97
15. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7
16. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598-604
17. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000; 342: 145-53
18. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
19. Steinhubl SR, Berger PB, Mann JT, et al., for the CREDO Investigators. Clopidogrel for the reduction of events during observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20
20. Northridge DB, Shandall A, Rees A, et al. Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit. Br Heart J 1994; 72: 466-7
21. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42
22. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316: 1430-4
23. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24 431 patients with coronary heart disease: survey in primary care. BMJ 2001; 322: 1463
24. Irving RJ, Oram SH, Boyd J, et al. Ten year audit of secondary prevention in coronary bypass patients. BMJ 2000; 321: 22-3
25. Holt ND, Johnson A, Davies A, et al. Secondary prevention in coronary artery disease: have we moved on from ASPIRE? Br J Cardiol 1999; 6: 584-8
26. Primesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322-5
27. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72
28. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82
29. EUROASPIRE II Steering Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001
30. Delacrétaz E, Michalopoulos PG, Ruiz J, et al. Management of hyperlipidaemia after coronary revascularisation: follow-up study. BMJ 1998; 316: 1499
31. Cohen MV, Byrne M, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83: 1294-304
32. Schectman G, Hiatt J. Drug therapy for hypercholesterolaemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204
33. Qureshi AI, Suri FK, Guterman LR, et al. Ineffective secondary prevention in survivors of cardiovascular events in the US population. Report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161: 1621-8
34. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82: 61-5
35. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-10
36. Schrott HG, Bittner V, Vittinghoff E, et al., for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. JAMA 1997; 277: 1281-6
37. Danias PG, O'Mahony S, Radford MJ, et al. Serum cholesterol levels are underevaluated and undertreated. Am J Cardiol 1998; 81: 1353-6
38. McCormick D, Gurwitz JH, Lessard D, et al. Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med 1999; 159: 561-7
39. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program Guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238-44
40. Elasy TA, Mehler PS. Secondary prevention practices after acute myocardial infarction in a large city hospital. Am J Cardiol 1998; 82: 987-9
41. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidaemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-7
42. Frolkis JP, Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines. Circulation 1998; 98: 851-5
43. Abookire SA, Karson AS, Fiskio J, et al. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-8
44. Yarzebski J, Spencer F, Goldberg RJ, et al. Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. Arch Intern Med 2001; 161: 1521-8
45. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (LTAP) A multicenter survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67
46. Massing MW, Sueta CA, Chowdhury M, et al. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001; 87: 646-9
47. Miller M, Byington R, Hunninghake D, et al., for the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the united states and canada. Arch Intern Med 2000; 160: 343-7
48. Smith DA, Harnick D, Kilaru R. Comparison of physician-managed lipid-lowering care in patients with coronary heart disease in two time periods (1994-1999). Am J Cardiol 2001; 88: 1417-9
49. Fonarow GC, French WJ, Parsons LS, et al., for the National Registry of Myocardial Infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction. Data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103: 38-44
50. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002; 176: 211-5
51. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997; 80 (8B): 45H-52H
52. Smith SC. Bridging the treatment gap. Am J Cardiol 2000; 85: 3E-7E
53. Vale MJ, Jelinek MV, Best JD, et al. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the 'real world': randomized controlled trial. J Clin Epidemiol 2002; 55: 245-52
54. Vale MJ, Jelinek MV, Best JD, et al. Coaching patients on achieving cardiovascular health (COACH): a multicenter randomized trial in patients with coronary heart disease. Arch Intern Med 2003; 163: 2775-83
55. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164: 208-11
56. Simons LA, Simons J, McManus P, et al. Discontinuation rates for use of statins is high [letter]. BMJ 2000; 321: 1084
57. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31
58. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-sectional study. JAMA 1998; 279: 1458-62
59. Houston Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-9
60. Glanz K. Compliance with dietary regimens: its magnitude, measurement, and determinants. Prev Med 1980; 9: 787-804
61. Oldridge NB. Compliance with cardiac rehabilitation services. J Cardiopulm Rehabil 1991; 11: 115-27
62. Henkin Y, Garber DW, Osterlund LC, et al. Saturated fats, cholesterol, and dietary compliance. Arch Intern Med 1992; 152: 1167-74
63. Burling TA, Singleton EG, Bigelow GE, et al. Smoking following myocardial infarction: a critical review of the literature. Health Psychol 1984; 3: 83-96
64. Hare DL, Bunker SJ. Cardiac rehabilitation and secondary prevention. Med J Aust 1999; 171: 433-9
65. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001; 345: 892-902
66. Wenger NK, Froehlicher ES, Smith LK, et al. Cardiac rehabilitation: clinical practice guidelines. Rockville (MD): Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, 1995. AHCPR publication no. 96-0672
67. Hare DL, Fitzgerald H, Darcy F, et al. Cardiac rehabilitation based on group light exercise and discussion. An Australian hospital model. J Cardiopulm Rehabil 1995; 15 (3): 186-92
68. Joliffe JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002
69. Thomas RJ, Houston Miller N, Lamendola C, et al. National survey on gender differences in cardiac rehabilitation programs: patient characteristics and enrollment patterns. J Cardiopulm Rehabil 1996; 16: 402-12
70. Harlan WR, Sandler SA, Lee KL, et al. Importance of baseline functional and socioeconomic factors for participation in cardiac rehabilitation. Am J Cardiol 1995; 76: 36-9
71. Pell J, Pell A, Morrison C, et al. Retrospective study of influence of deprivation of uptake of cardiac rehabilitation. BMJ 1996; 313: 267-8
72. Bunker S, McBurney H, Cox H, et al. Identifying participation rates at outpatient cardiac rehabilitation programs in Victoria, Australia. J Cardiopulm Rehabil 1999; 19: 334-8
73. Scott IA, Lindsay KA, Harden HE. Utilisation of outpatient cardiac rehabilitation in Queensland. Med J Aust 2003; 179 (7): 341-5
74. Sundararajan V, Bunker SJ, Begg S, et al. Attendance rates and cardiac rehabilitation in Victoria, 1998. Med J Aust 2004; 180: 268-71
75. Bero LA, Grilli R, Grimshaw JM. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998; 317: 465-8
76. DeBusk RF, Houston Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction: MULTIFIT. Ann Intern Med 1994; 120: 721-9
77. Stagmo M, Westin L, Carlsson R, et al. Long-term effects on cholesterol levels and utilization of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease. J Cardiovasc Risk 2001; 8: 243-8
78. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol ≤100 mg/dl. Am J Cardiol 2000; 85: 305-8
79. Senaratne MPJ, Griffiths J, Mooney D, et al. Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. Am Heart J 2001; 142: 975-81
80. Heller RF, Knapp JC, Valenti LA, et al. Secondary prevention after acute myocardial infarction. Am J Cardiol 1993; 72: 759-62
81. Kirkman MS, Weinberger M, Landsman PB, et al. A telephone-delivered intervention for patients with NIDDM. Diabetes Care 1994; 17: 840-6
82. Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk. BMJ 1994; 309: 993-6
83. Cupples ME, McKnight A. Five year follow up of patients at high cardiovascular risk who took part in randomised controlled trial of health promotion. BMJ 1999; 319: 687-8
84. Tooth LR, McKenna KT, Maas F. Pre-admission education/counselling for patients undergoing coronary angioplasty: impact on knowledge and risk factors. Aust N Z J Public Health 1998; 22: 583-8
85. Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ 1999; 318: 706-15
86. Holt N, Johnson A, de Belder M. Patient empowerment in secondary prevention of coronary heart disease [letter]. Lancet 2000; 356: 314
87. Lear SA, Ignaszewski A, Linden W, et al. The extensive lifestyle management intervention (ELMI) following cardiac rehabilitation trial. Eur Heart J 2003; 24: 1920-7
88. Murchie P, Campbell NC, Ritchie LD, et al. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ 2003; 326: 84
89. Scott IA, Denaro CP, Bennett CJ, et al. Achieving better in-hospital and after-hospital care of patients with acute cardiac disease. MJA 2004; 180 (10 Suppl.): S83-8
90. Ferry CT, Fitzpatrick MA, Long PW. Towards a safer culture: clinical pathways in acute coronary syndromes and stroke. MJA 2004; 180 (10 Suppl.): S92-6
91. Fonarow GC, Gawlinksi A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP) Am J Cardiol 2001; 87: 819-22
92. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87: 257-61
93. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6
94. Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8
95. McAlister FA, Lawson FME, Teo KK, et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001; 323: 957-62
96. Cohen LL, Blount RL, Panopoulos G. Nurse coaching and cartoon distraction: an effective and practical intervention to reduce child, parent, and nurse distress during immunizations. J Pediatr Psychol 1997; 22: 355-70
97. Manne SL, Redd WH, Jacobsen PB, et al. Behavioral intervention to reduce child and parent distress during venipuncture. J Consult Clin Psychol 1990; 58: 565-72
98. Manne SL, Bakeman R, Jacobsen PB, et al. An analysis of a behavioral intervention for children undergoing venipuncture. Health Psychol 1994; 13: 556-66
99. Zelikovsky N, Rodrigue JR, Gidycz CA, et al. Cognitive behavioral and behavioral interventions to help young children cope during a voiding cystourethrogram. J Pediatr Psychol 2000; 25: 535-43
100. Foertsch CE, O'Hara MW, Stoddard FJ, et al. Parent participation during burn debridement in relation to behavioral distress. J Burn Care Rehabil 1996; 17: 372-7
101. Blount RL, Powers SW, Cotter MW, et al. Making the system work: training pediatric oncology patients to cope and their parents to coach them during BMA/LP procedures. Behav Modif 1994; 18: 6-31
102. Oliver JW, Kravitz RL, Kaplan SH, et al. Individualized patient education and coaching to improve pain control among cancer outpatients. J Clin Oncol 2001; 19: 2206-12
103. Wilkie DJ, Williams AR, Grevstad P, et al. Coaching persons with lung cancer to report sensory pain: literature review and pilot study findings. Cancer Nurs 1995; 18: 7-15
104. Brown R, Butow PN, Boyer MJ, et al. Promoting patient participation in the cancer consultation: evaluation of a prompt sheet and coaching in question-asking. Br J Cancer 1999; 80: 242-8
105. Samarel N, Fawcett J. Enhancing adaptation to breast cancer: the addition of coaching to support groups. Oncol Nurs Forum 1992; 19: 591-6
106. Samarel N, Fawcett J, Tulman L. The effects of coaching in breast cancer support groups: a pilot study. Oncol Nurs Forum 1993; 20: 795-8
107. Samarel N, Fawcett J, Tulman L. Effect of support groups with coaching on adaptation to early stage breast cancer. Res Nurs Health 1997; 20: 15-26
108. Garfinkel M, Blumenthal E. 'Co-active coaching' could help HIV patients: new type of counseling involves goal-setting. AIDS Alert 2001; 16: 105-8
109. Fitts SS, Guthrie MR, Blagg CR. Exercise coaching and rehabilitation counseling improve quality of life for predialysis and dialysis patients. Nephron 1999; 82: 115-21
110. Carrieri-Kohlman V, Gormley JM, Douglas MK, et al. Exercise training decreases dyspnea and the distress and anxiety associated with it: monitoring alone may be as effective as coaching. Chest 1996; 110: 1526-35
111. Carrieri-Kohlman V, Gormley JM, Eiser S, et al. Dyspnea and the affective response during exercise training in obstructive pulmonary disease. Nurs Res 2001; 50: 136-46
112. Jonkers CF, Prins F, Van Kempen A, et al. Towards implementation of optimum nutrition and better clinical nutrition support. Clin Nutr 2001; 20: 361-6
113. Scott LK, Scott CW, Palmisano PA, et al. The effects of commercial coaching on the NBME Part I Examination. J Med Educ 1980; 55: 733-42
114. Jackevicius CA, Chapman KR. Inhaler education for hospital-based pharmacists: how much is required? Can Respir J 1999; 6: 237-44
115. Lewis CK. The clinical nurse specialist's role as coach in a clinical practice development model. J Vasc Nurs 1996; 14: 48-52
116. Breslin EH. Prevention and treatment of pulmonary complications in patients after surgery of the upper abdomen. Heart Lung 1981; 10: 511-9
117. Dunn SM, Beeney LJ, Hoskins PL, et al. Knowledge and attitude change as predictors of metabolic improvement in diabetes education. Soc Sci Med 1990; 31: 1135-41
118. Moher D, Schulz KF, Altman DG, for the CONSORT Group, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4
119. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. Lipid Management Guidelines 2001. Med J Aust 2001; 175 (5 November Suppl.): S57-S85
120. National Heart Foundation of Australia homepage [online]. Available from URL: http://www.heartfoundation.com.au [Accessed 2005 Apr 19]
121. Zimmet P, Alberti G, de Courten MP. New classification and criteria for diabetes: moving the goalposts closer. Med J Aust 1998; 168: 593-4
122. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva: WHO, 1995. Technical report series 854
123. Ireland P, Jolley D, Giles G, et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethically diverse cohort. Asia Pacific J Clin Nutr 1994; 3: 19-31
124. Hare DL, Davis CR. Cardiac depression scale: validation of a new depression scale for cardiac patients. J Psychosom Res 1996; 40: 379-86
125. Spielberger CD, Gorsuch RL, Lushene RE. State-trait anxiety inventory. STAI Manual. Consulting Psychologists Press, Inc., 1970: 3-8
126. Wood PD, Haskell WL. The effect of exercise on plasma high density lipoproteins. Lipids 1979; 14: 417-27
127. Schneider RA, Costiloe JP, Wolf S. Arterial pressures recorded in hospital and during ordinary daily activities: contrasting data in subjects with and without ischemic heart disease. J Chronic Dis 1971; 23: 647-57
128. Lewin RJ, Furze G, Robinson J, et al. A randomised controlled trial of a self-management plan for patients with newly diagnosed angina. Br J Gen Pract 2002; 52: 194-201